Akebia Therapeutics Inc.

3.06-0.1000-3.16%Vol 2.95M1Y Perf -56.14%
Apr 9th, 2021 16:00 DELAYED
BID3.06 ASK3.10
Open3.17 Previous Close3.16
Pre-Market- After-Market3.06
 - -  - -%
Target Price
9.43 
Analyst Rating
Strong Buy 1.50
Potential %
208.17 
Finscreener Ranking
★★+     49.35
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     45.99
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★     46.67
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap469.72M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
8.35 
Earnings Date
4th May 2021

Today's Price Range

3.063.17

52W Range

2.0913.71

5 Year PE Ratio Range

-3.10-3.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.11%
1 Month
-13.07%
3 Months
-1.29%
6 Months
-1.61%
1 Year
-56.14%
3 Years
-69.31%
5 Years
-67.99%
10 Years
-

TickerPriceChg.Chg.%
AKBA3.06-0.1000-3.16
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
1.60
2.00
0.33
0.51
-55.20
Leverage Ratio 2.20
ProfitabilityValueIndustryS&P 500US Markets
-0.20
-124.90
-113.30
-1 836.90
-83.74
RevenueValueIndustryS&P 500US Markets
206.83M
1.35
17.37
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.43-0.60-39.53
Q03 2020-0.23-0.42-82.61
Q02 2020-0.46-0.444.35
Q01 2020-0.63-0.4725.40
Q04 2019-0.45-0.61-35.56
Q03 2019-0.37-0.2824.32
Q02 2019-0.35-0.3014.29
Q01 2019-0.42-0.44-4.76
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.33-17.86Negative
6/2021 QR-0.30-7.14Negative
12/2021 FY-1.13-56.94Negative
12/2022 FY-0.49-16.67Negative
Next Report Date4th May 2021
Estimated EPS Next Report-0.33
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume2.95M
Shares Outstanding153.50M
Trades Count9.73K
Dollar Volume53.11M
Avg. Volume6.43M
Avg. Weekly Volume3.71M
Avg. Monthly Volume4.45M
Avg. Quarterly Volume6.58M

Akebia Therapeutics Inc. (NASDAQ: AKBA) stock closed at 3.06 per share at the end of the most recent trading day (a -3.16% change compared to the prior day closing price) with a volume of 2.99M shares and market capitalization of 469.72M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 360 people. Akebia Therapeutics Inc. CEO is John P. Butler.

The one-year performance of Akebia Therapeutics Inc. stock is -56.14%, while year-to-date (YTD) performance is 9.29%. AKBA stock has a five-year performance of -67.99%. Its 52-week range is between 2.09 and 13.71, which gives AKBA stock a 52-week price range ratio of 8.35%

Akebia Therapeutics Inc. currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 2.10, a price-to-sale (PS) ratio of 2.47, a price to cashflow ratio of 10.50, a PEG ratio of 2.32, a ROA of -51.69%, a ROC of -84.56% and a ROE of -113.21%. The company’s profit margin is -83.74%, its EBITDA margin is -113.30%, and its revenue ttm is $206.83 Million , which makes it $1.35 revenue per share.

Of the last four earnings reports from Akebia Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.33 for the next earnings report. Akebia Therapeutics Inc.’s next earnings report date is 04th May 2021.

The consensus rating of Wall Street analysts for Akebia Therapeutics Inc. is Strong Buy (1.5), with a target price of $9.43, which is +208.17% compared to the current price. The earnings rating for Akebia Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Akebia Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Akebia Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.02, ATR14 : 0.35, CCI20 : -61.81, Chaikin Money Flow : -0.15, MACD : -0.12, Money Flow Index : 36.50, ROC : -12.41, RSI : 46.90, STOCH (14,3) : 33.73, STOCH RSI : 1.00, UO : 50.10, Williams %R : -66.27), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Akebia Therapeutics Inc. in the last 12-months were: Cynthia Smith (Sold 4 567 shares of value $55 261 ), David A. Spellman (Sold 790 shares of value $2 686 ), Dell Faulkingham (Sold 21 505 shares of value $178 220 ), John P. Butler (Sold 54 099 shares of value $183 742 ), Maxine Gowen (Sold 4 567 shares of value $55 032 ), Michel Dahan (Sold 15 758 shares of value $53 520 ), Nicole R. Hadas (Sold 15 345 shares of value $52 117 ), Steven C. Gilman (Sold 4 567 shares of value $55 169 ), Steven Keith Burke (Sold 8 639 shares of value $29 343 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (66.67 %)
4 (66.67 %)
4 (57.14 %)
Moderate Buy
1 (16.67 %)
1 (16.67 %)
1 (14.29 %)
Hold
1 (16.67 %)
1 (16.67 %)
2 (28.57 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.50
Moderate Buy
1.71

Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

CEO: John P. Butler

Telephone: +1 617 871-2098

Address: 245 First Street, Cambridge 02142, MA, US

Number of employees: 360

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

60%40%

Bearish Bullish

60%40%

News

Stocktwits